EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Craniospinal irradiation and/or intraventricular radioimmunotherapy after high‐dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes

Sameer Farouk Sait iD, Nancy A Kernan, Elizabeth Klein iD, Barbara Spitzer, Carolyn Fein Levy iD, Jonathan Fish iD, Onur Yildirim, Sofia Haque, Maria Donzelli, Mauricio Rendon Bernot, David H Abramson, Jasmine H Francis und 7 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31297 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Sameer Farouk Sait und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Craniospinal Irradiation, Radioimmunotherapy, Retinoblastoma, Transplantation, Autologous. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI Cancer Center Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis for patients with central nervous system (CNS) retinoblastoma (RB) (trilateral or stage 4b metastatic RB) treated with high‐dose chemotherapy and autologous stem cell transplant (HDC‐ASCT) remains poor. The impact of irradiation when administered as part of upfront therapy post HDC‐ASCT on treatment outcomes and survival is unknown.

Methods

We performed a retrospective review of all patients with CNS RB (seven stage 4b, eight trilateral, one pineal lesion belonging to methylation group RB) who underwent induction chemotherapy with an intent to proceed to HDC‐ASCT at two institutions.

Results

Twelve of 16 patients ( n = 75%) achieved an objective response to induction chemotherapy, while four patients had progressive/refractory disease; two patients responded to subsequent therapy and proceeded to ASCT, and two patients did not. Seven of 14 patients who underwent HDC‐ASCT, received radiotherapy as part of upfront therapy post HDC‐ASCT in the form of craniospinal irradiation (CSI) ( n = 3), intraventricular radioimmunotherapy ( n = 3), or both CSI and intraventricular radioimmunotherapy ( n = 1). The Kaplan–Meier estimate of overall survival for these patients was 62.5% at 5 years; no patients developed second malignant neoplasms within the radiation fields. For the seven patients who did not receive radiotherapy, the overall survival was 28.6% at 5 years.

Conclusions

CSI (23.4 Gy) alone or in conjunction with intraventricular RIT may have clinical utility in eliminating persistent MRD post HDC‐ASCT, contributing to improved disease‐free survival in patients with CNS RB. This treatment strategy merits evaluation in a prospective, multicenter clinical trial for patients with CNS metastatic RB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Craniospinal IrradiationRadioimmunotherapyRetinoblastomaTransplantation, AutologousHumansMaleFemaleRetrospective StudiesChild, PreschoolChildInfantCombined Modality TherapySurvival RateCentral Nervous System NeoplasmsRetinal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAdolescentFollow-Up StudiesStem Cell TransplantationPrognosisInduction ChemotherapyHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

CNS metastatic retinoblastomacompartmental radioimmunotherapyradiotherapy

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
  • Pediatric Neuro-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Pediatric Stem Cell Transplantation and Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Hackensack University Medical Center, Hackensack, New Jersey, USA.

ORCID-Profile: Sameer Farouk Sait, Elizabeth Klein, Carolyn Fein Levy, Jonathan Fish, Matthias Karajannis, Stephen Sands, Suzanne Wolden, Ira J Dunkel

Förderung

  • NCI NIH HHS
  • NCI Cancer Center Support

Zitieren

APA

Sait, S. F., Kernan, N. A., Klein, E., Spitzer, B., Levy, C. F., Fish, J., Yildirim, O., Haque, S., Donzelli, M., Bernot, M. R., Abramson, D. H., Francis, J. H., Khakoo, Y., Karajannis, M., Sands, S., Pandit-Taskar, N., Wolden, S., Kramer, K., & Dunkel, I. J. (2024). Craniospinal irradiation and/or intraventricular radioimmunotherapy after high‐dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31297

Vancouver

Sait SF, Kernan NA, Klein E, Spitzer B, Levy CF, Fish J, et al. Craniospinal irradiation and/or intraventricular radioimmunotherapy after high‐dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31297

BibTeX
@article{Sait2024,
  author = {Sait, Sameer Farouk and Kernan, Nancy A and Klein, Elizabeth and Spitzer, Barbara and Levy, Carolyn Fein and Fish, Jonathan and Yildirim, Onur and Haque, Sofia and Donzelli, Maria and Bernot, Mauricio Rendon and Abramson, David H and Francis, Jasmine H and Khakoo, Yasmin and Karajannis, Matthias and Sands, Stephen and Pandit-Taskar, Neeta and Wolden, Suzanne and Kramer, Kim and Dunkel, Ira J},
  title = {Craniospinal irradiation and/or intraventricular radioimmunotherapy after high‐dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31297}
}
Kostenlos starten →